Prescient Therapeutics : Application for quotation of securities - PTX

For personal use only

Entity name

PRESCIENT THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Tuesday November 30, 2021

The +securities to be quoted are:

Other

Total number of +securities to be quoted

Refer to next page for full details of the announcement

For personal use only

1.1 Name of entity

PRESCIENT THERAPEUTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1. The announcement is New announcement
2. Date of this announcement

30/11/2021

For personal use only

2.2 The +securities to be quoted are:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Refer to Resolution 3 of the Company's Notice of 2021 Annual General Meeting -https://cdn-api.markitdigital.com/apiman

-gateway/ASX/asx-research/1.0/file/2924-02432056-3A577594?access_token=83ff96335c2d45a094df02a206a39ff4

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

For personal use only

Additional +securities to be quoted in an existing class

ASX +security code and description

PTX : ORDINARY FULLY PAID

Issue date

30/11/2021

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

For personal use only

Number of +securities to be quoted

2,000,000

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Issue of Share under Loan Funded Share Plan

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.150000

Any other information the entity wishes to provide about the +securities to be quoted

None

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

Refer to Resolution 3 of the Company's 2021 Notice of Annual General Meeting -https://cdn-api.markitdigital.com/apiman

-gateway/ASX/asx-research/1.0/file/2924-02432056-3A577594?access_token=83ff96335c2d45a094df02a206a39ff4

Number of +securities to be quoted

2,000,000

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Issue of Share under Loan Funded Share Plan

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.220000

Any other information the entity wishes to provide about the +securities to be quoted

None

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

Refer to Resolution 3 of the Company's 2021 Notice of Annual General Meeting -https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02432056-3A577594?access_token=83ff96335c2d45a094df02a206a39ff4